633. Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) Efficacy in Participants with Pre-Existing Primary Integrase Inhibitor Resistance Through 48 Weeks of Phase 3 Clinical Trials

BACKGROUND: Pre-existing drug resistance can affect the efficacy of antiretroviral therapy. Studies in treatment-naïve and virologically suppressed participants have demonstrated safety and efficacy of B/F/TAF, including in patients with M184V/I mutations. In this pooled analysis, we investigated vi...

Descripción completa

Detalles Bibliográficos
Autores principales: D’Antoni, Michelle L, Andreatta, Kristen, Acosta, Rima K, Chang, Silvia, Martin, Ross, White, Kirsten L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777236/
http://dx.doi.org/10.1093/ofid/ofaa439.827

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7777236/
http://dx.doi.org/10.1093/ofid/ofaa439.827

Ejemplares similares